The emergence of powerful oral anti-COVID-19 drugs in the post-vaccine era.
作者信息
Fan Huahao, Lou Fuxing, Fan Junfen, Li Maochen, Tong Yigang
机构信息
College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
Institute of Cerebrovascular Disease Research and Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China.
出版信息
Lancet Microbe. 2022 Feb;3(2):e91. doi: 10.1016/S2666-5247(21)00278-0. Epub 2021 Nov 25.
Abstract
摘要
相似文献
1
The emergence of powerful oral anti-COVID-19 drugs in the post-vaccine era.疫苗接种后时代强效口服抗新冠病毒药物的出现。
Lancet Microbe. 2022 Feb;3(2):e91. doi: 10.1016/S2666-5247(21)00278-0. Epub 2021 Nov 25.
2
Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines.新型 COVID-19 变种及其对 SARS-CoV-2 诊断、治疗和疫苗的影响。
Ann Med. 2022 Dec;54(1):524-540. doi: 10.1080/07853890.2022.2031274.
3
Repurposing of the childhood vaccines: could we train the immune system against the SARS-CoV-2.重新利用儿童疫苗：我们能否训练免疫系统对抗 SARS-CoV-2。
Expert Rev Vaccines. 2021 Sep;20(9):1051-1057. doi: 10.1080/14760584.2021.1960161. Epub 2021 Aug 6.
4
Mapping the technological landscape of SARS, MERS, and SARS-CoV-2 vaccines.绘制 SARS、MERS 和 SARS-CoV-2 疫苗的技术图谱。
Drug Dev Ind Pharm. 2021 Apr;47(4):673-684. doi: 10.1080/03639045.2021.1908343. Epub 2021 Apr 7.
5
SARS-CoV-2: Unique Challenges of the Virus and Vaccines.SARS-CoV-2：病毒和疫苗的独特挑战。
Immunol Invest. 2021 Oct;50(7):802-809. doi: 10.1080/08820139.2021.1936009. Epub 2021 Jun 10.
6
COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.COVID-19 疫苗：辉瑞/生物科技和 Moderna 疫苗的生物学、药理学特征和不良反应比较。
Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1663-1669. doi: 10.26355/eurrev_202102_24877.
7
Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.辉瑞-生物科技和 Moderna 疫苗在 SARS-CoV-2 B.1.617.2（Delta）变异株广泛传播之前和期间预防养老院居民感染 SARS-CoV-2 的有效性 - 国家医疗保健安全网络，2021 年 3 月 1 日至 8 月 1 日。
MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1163-1166. doi: 10.15585/mmwr.mm7034e3.
8
Recent Advances on Drugs and Vaccines for COVID-19.新冠病毒药物和疫苗的最新进展
Inquiry. 2021 Jan-Dec;58:469580211055630. doi: 10.1177/00469580211055630.
9
Letter to the editor to: Verger P and Dubé E. Restoring confidence in vaccines in the COVID-19 era, expert review of vaccines, 2020; 19(11):991-3.致编辑的信：致韦尔热·P和迪贝·E。《在新冠疫情时代恢复对疫苗的信心》，《疫苗专家评论》，2020年；19(11):991 - 3。
Expert Rev Vaccines. 2021 Apr;20(4):479-481. doi: 10.1080/14760584.2021.1903880. Epub 2021 Apr 5.
10
The COVID-19 pandemic: viral variants and vaccine efficacy.新型冠状病毒肺炎大流行：病毒变异株与疫苗效力。
Crit Rev Clin Lab Sci. 2022 Jan;59(1):66-75. doi: 10.1080/10408363.2021.1979462. Epub 2021 Oct 1.
引用本文的文献
1
Real-World Efficacy of Ensitrelvir in Hospitalized Patients With COVID-19 in Japan: A Retrospective Observational Study.恩西他韦在日本新冠肺炎住院患者中的真实世界疗效：一项回顾性观察研究。
Cureus. 2024 May 25;16(5):e61048. doi: 10.7759/cureus.61048. eCollection 2024 May.
2
Bioluminescence imaging reveals enhanced SARS-CoV-2 clearance in mice with combinatorial regimens.生物发光成像显示联合治疗方案可增强小鼠体内新冠病毒的清除。
iScience. 2024 Jan 30;27(3):109049. doi: 10.1016/j.isci.2024.109049. eCollection 2024 Mar 15.
3
Taking stock of the mutations in human SARS-CoV-2 spike proteins: From early days to nearly the end of COVID-19 pandemic.盘点人类严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突蛋白的突变：从新冠疫情初期到接近尾声
Curr Res Struct Biol. 2023 Oct 5;6:100107. doi: 10.1016/j.crstbi.2023.100107. eCollection 2023.
4
Metallic nanoplatforms for COVID-19 diagnostics: versatile applications in the pandemic and post-pandemic era.用于 COVID-19 诊断的金属纳米平台：大流行及大流行后时代的多功能应用。
J Nanobiotechnology. 2023 Aug 4;21(1):255. doi: 10.1186/s12951-023-01981-5.
5
COVID-19 in early 2023: Structure, replication mechanism, variants of SARS-CoV-2, diagnostic tests, and vaccine & drug development studies.2023年初的新型冠状病毒肺炎：严重急性呼吸综合征冠状病毒2的结构、复制机制、变体、诊断测试以及疫苗与药物研发研究
MedComm (2020). 2023 Apr 8;4(2):e228. doi: 10.1002/mco2.228. eCollection 2023 Apr.
6
The shift of percent excess mortality from zero-COVID policy to living-with-COVID policy in Singapore, South Korea, Australia, New Zealand and Hong Kong SAR.新加坡、韩国、澳大利亚、新西兰和中国香港特别行政区从“零新冠”政策向“与新冠共存”政策转变的超额死亡率百分比。
Front Public Health. 2023 Mar 20;11:1085451. doi: 10.3389/fpubh.2023.1085451. eCollection 2023.
7
Coronavirus Inhibitors Targeting nsp16.冠状病毒 nsp16 靶向抑制剂。
Molecules. 2023 Jan 18;28(3):988. doi: 10.3390/molecules28030988.
8
Luteolin-rich fraction from seed meal inhibits spike glycoprotein S1 of SARS-CoV-2-induced NLRP3 inflammasome lung cell inflammation regulation of JAK1/STAT3 pathway: A potential anti-inflammatory compound against inflammation-induced long-COVID.来自种子粕的富含木犀草素的组分抑制SARS-CoV-2诱导的NLRP3炎性小体肺细胞炎症中刺突糖蛋白S1，JAK1/STAT3通路的调节：一种针对炎症诱导的长期新冠的潜在抗炎化合物。
Front Med (Lausanne). 2023 Jan 9;9:1072056. doi: 10.3389/fmed.2022.1072056. eCollection 2022.
9
The Effect of Preventive Measures and Vaccination against SARS-CoV-2 on the Infection Risk, Treatment, and Hospitalization: A Cross-Sectional Study of Algeria.《预防措施和 SARS-CoV-2 疫苗接种对感染风险、治疗和住院的影响：阿尔及利亚的横断面研究》。
Viruses. 2022 Dec 12;14(12):2771. doi: 10.3390/v14122771.
10
Nucleic acid strategies for infectious disease treatments: The nanoparticle-based oral delivery route.传染病治疗的核酸策略：基于纳米颗粒的口服给药途径。
Front Pharmacol. 2022 Aug 29;13:984981. doi: 10.3389/fphar.2022.984981. eCollection 2022.
本文引用的文献
1
Molnupiravir: coding for catastrophe.莫努匹拉韦：引发灾难的编码。
Nat Struct Mol Biol. 2021 Sep;28(9):706-708. doi: 10.1038/s41594-021-00657-8.
2
Rethinking Remdesivir: Synthesis, Antiviral Activity, and Pharmacokinetics of Oral Lipid Prodrugs.重新思考瑞德西韦：口服脂质前药的合成、抗病毒活性和药代动力学。
Antimicrob Agents Chemother. 2021 Sep 17;65(10):e0115521. doi: 10.1128/AAC.01155-21. Epub 2021 Jul 26.
3
β-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells.β-d-N4-羟基胞苷通过致命诱变抑制 SARS-CoV-2，但对哺乳动物细胞也具有诱变作用。
J Infect Dis. 2021 Aug 2;224(3):415-419. doi: 10.1093/infdis/jiab247.
4
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.一种口服生物利用度的广谱抗病毒药物可抑制人呼吸道上皮细胞培养中的 SARS-CoV-2 病毒和小鼠中的多种冠状病毒。
Sci Transl Med. 2020 Apr 29;12(541). doi: 10.1126/scitranslmed.abb5883. Epub 2020 Apr 6.
Zotero 插件